Immunoglobulin A Nephropathy (IgAN) has historically been managed as a slowly progressive condition treated primarily with supportive care. That paradigm is shifting. With multiple targeted, disease-modifying therapies now FDA-approved across distinct mechanistic classes, the market is entering a more competitive and clinically complex phase, one where treatment decisions, payer policy, and drug development strategy are all being reshaped in parallel. 

This report examines five trends likely to determine competitive positioning as the market matures. It addresses a central tension in the field: regulatory approvals have largely relied on short-term proteinuria endpoints, yet nephrologists broadly regard these as interim measures, raising the question of what evidence will ultimately determine which therapies become standard of care. Beyond clinical data, the report explores how real-world factors are shaping prescribing patterns in ways that don't always track with efficacy alone. Finally, it identifies structural gaps in the current landscape that remain open for future differentiation. 

Together, these trends offer a framework for understanding not just where the IgAN market stands today, but where competitive advantage is likely to be won or lost as it continues to evolve.